Successful Management of a Chronic Refractory Leg Ulcer in an Adolescent with Sickle Cell Anemia by Giovanni Paolino et al.
213ACTA DERMATOVENEROLOGICA CROATICA
Successful Management of a Chronic Refractory Leg 
Ulcer in an Adolescent with Sickle Cell Anemia
Giovanni Paolino1, Michelina Santopietro2,Giovanna Palumbo2, Maria 
Giuseppina Onesti3, Alessandra Micozzi2, Salvatore Venosi4, Marica 
Laurino2, Giancarlo Ferrazza2, Pasquale Fino3, Robin Foà2, Fiorina Giona2
1Dermatologic Clinic, Sapienza University of Rome, Rome, Italy; 2Hematology, De-
partment of Cellular Biotechnologies and Hematology, Sapienza University of Rome, 
Rome, Italy; 3Department of Plastic, Reconstructive and Aesthetic Surgery, Sapienza 
University of Rome, Policlinico Umberto I, Rome, Italy; 4Vascular Surgery, Department 




La Sapienza University of Rome




Received: March 30, 2015
Accepted: August 20, 2015
Acta Dermatovenerol Croat 2015;23(3):213-217                  CASE REPORT
ABSTRACT Sickle cell disease (SCD) is an inherited hemoglobin-
opathy characterized by a wide range of clinical manifestations. 
Chronic leg ulcers are a disabling complication with repercus-
sions on the quality of life. We report the case of a 14-year-old 
girl with a diagnosis of SCD who developed a chronic leg ulcer 
that was successfully treated with a multi-disciplinary approach, 
including local and systemic therapies. The role of different treat-
ments, in particular low molecular weight heparin, in the refrac-
tory chronic leg ulcer healing process will be discussed. 
KEY WORDS: sickle cell disease; chronic leg ulcer; hydroxyurea; 
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INTRODUCTION
Sickle cell disease (SCD), an inherited hemoglo-
binopathy, is a multi-system disease characterized by 
a wide range of clinical manifestations that can result 
in pain, organ injury, and early mortality (1). Leg ulcers 
are a serious and disabling complication with a signifi-
cant impact on the quality of life in patients with SCD, 
especially adolescents (1,2). Currently, most of the 
therapies offered to patients with SCD are support-
ive (e.g. antibiotics, routine immunizations, transfu-
sions, hydration, and narcotic therapy to treat painful 
events) and do little to change the underlying patho-
physiology of the disease (1). There are no definitive 
treatment guidelines available, and hydroxyurea (HU) 
is considered the only disease-modifying therapy for 
SCD. While such treatment may effectively control 
SCD, at the same time it can also induce side effects. 
It may be difficult for the clinician to distinguish if the 
cause is related to the disease itself or to the treat-
ment with many related patient management prob-
lems, especially at the pediatric age (1). Hereby, we 
report a case of chronic leg ulcer that developed in a 
young girl with SCD during treatment with HU.
CASE REPORT
A 14-year-old girl from Ghana came to our In-
stitute with a painful cutaneous ulcer in the medial 
lower third of her left leg (Figure 1, A). The patient de-
nied possible traumatic origin of the leg ulcer; labora-
tory investigations showed a low hemoglobin value 
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of 7.6 g/dL with a reticulocyte count of 417 000 and 
a hematocrit of 22.8%, high white blood cell counts 
(13.54 ×109/L; with 51% neutrophils and 36% lym-
phocytes), a normal platelet count (286 ×109/L), and 
high levels of bilirubin (2.12 mg/dL, direct 0.4 mg/dL), 
lactate dehydrogenase (318 U/L, with a normal upper 
range of 190 U/L), and ferritin (1 890 ng/mL). Other 
biochemical parameters, including those that could 
influence clotting, were within the normal ranges. 
Chest radiography was normal, as well as eco-color 
Doppler of the lower limbs.
She was first diagnosed with homozygous SCD 
(quantitative analysis of 56.5% of hemoglobin S 
(HbS)) at the age of 2 years. The girl did not need red 
blood cell (RBC) transfusions until the age of 10, when 
she presented with pains in the legs and arms com-
bined with severe anemia (5.6 g/dL) and required RBC 
transfusion. In the subsequent years, she experienced 
several vaso-occlusive episodes with limb pains, os-
teonecrosis of the femoral head, interstitial pneumo-
nia, and osteomyelitis of the 4th dorsal vertebra. Addi-
tionally, she required a RBC transfusion regimen con-
sisting of one transfusion every 3 weeks. At the age of 
11, it was decided to start therapy with HU and folic 
acid in order to reduce transfusion requirements and 
the clinical manifestations. Progressive improvement 
of the painful symptoms was noted starting from the 
first month of treatment with HU. Furthermore, a de-
crease in RBC transfusion requirements to one trans-
fusion every 2 months was observed.
Ten months before the appearance of the leg ul-
cer, the patient suffered from interstitial pneumonia 
and synovitis with blood cultures positive for coagu-
lase-negative staphylococci, successfully treated with 
levofloxacin and piperacillin-tazobactam. An 8 by 
4.5 cm wound appeared above the left medial mal-
leolus 9 months after recovery from pneumonia, with 
no traumatic event to cause it. At the beginning the 
wound showed partial thickness skin loss, abrasion, 
and a shallow crater (stage II) (Figure 1, A). A multi-
disciplinary approach was used to manage this com-
plication. The bacterial culture was positive for both 
Gram+ and Gram– agents and, accordingly, a long-
term treatment with specific antibacterial agents was 
administered. Several surgical curettages were per-
formed on an inpatient basis. Meanwhile, iron che-
Figure 1. (A) Wound with partial thickness skin loss, presenting an abrasion and a shallow crater; (B) after about 
10 months the ulcer extended, with full thickness skin loss, involving damage to the subcutaneous tissue; (C) at 
23 months, the wound showed an initial reduction ≥20-30%; (D) after 39 months the ulcer completely closed 
and the painful symptoms completely disappeared.
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lation therapy with deferasirox was started because 
of the increased plasma ferritin values. However, the 
ulcer extended with full thickness skin loss, involving 
damage to the subcutaneous tissue; it presented as a 
deep crater with undermining of the adjacent tissue 
(stage III) (Figure 1, B). It is important to note that the 
patient was poorly compliant to both treatment and 
medical controls, probably due to youth age and so-
cio-economic status. Accordingly, we decided to treat 
her as an inpatient with Negative Pressure Wound 
Therapy (NPWT) for 10 days, which resulted in mini-
mal improvement of the lesion (3). We also performed 
daily medication of ulcerative lesions, disinfecting 
them with sodium hypochlorite 0.05% cutaneous so-
lution, a cutaneous solution based on 10% povidone 
iodine, and applying a film of about 2 mL of Bionect 
Start® (a topical cream containing hyaluronate acid, 
bacterial fermented sodium hyalunorate salt, and 
bacterial collagenase obtained from nonpathogenic 
Vibrio alginolyticus) ointment on the lesions and zinc 
oxide paste onto the surrounding skin. At the same 
time, two skin grafts were also performed, without 
engraftment. The patient presented with progressive 
anemia (hemoglobin 5.7%), with significant increase 
in transfusion requirements (1 RBC transfusion every 
twenty days, then weekly). 
One year later, despite adequate care, an increase 
of the ulcer was noticed combined with an underly-
ing osteomyelitis. Accordingly, a different therapeutic 
approach was planned: surgical curettages, an eryth-
rocytes-apheresis procedure, and intravenous broad-
spectrum antibiotic therapy were combined with ap-
plications of a platelet gel (PLT-gel) counterpart (4). 
The platelet-rich plasma was obtained by centrifug-
ing the blood so that the components were separated 
by density gradient. The final product was a gel rich in 
growth factors that act in tissue repair by activating 
fibroblasts and inducing extracellular matrix remod-
eling. HU was discontinued at this time, 23 months 
after the onset of the leg wound. No improvement 
of the leg ulcer after 2 months of this treatment was 
observed. 
Consequently, we decided to change the treat-
ment strategy. Local therapy with weekly elastic ban-
dage compression type Peha-Haft-knee, irrigation 
with saline solution (0.9% NaCl) every 2 hours and 
boric acid 3% once a day, combined with systemic 
treatment with enoxaparin, a low molecular weight 
heparin (LMWH), at 4.000 IU daily given subcutane-
ously, and intra-venous antibiotic therapy were start-
ed. The wound decreased by 20-30% over 1 month 
(Figure 1, C) and the fast healing process allowed us 
to replace the elastic bandage compression with a 
knee-high elastic stocking type. A topical cream with 
Vitamin E was also employed to ease tissue repair. Af-
ter one week, the leg ulcer was found to be colonized 
by Extended-spectrum beta-lactamases postitive 
Escherichia coli (E. Coli ESBL+), for which a targeted 
antibiotic treatment intravenously for 3 weeks was 
installed. 
LMWH was continued for a total of 3 months. 
Meanwhile, the ulcer continued to shrink in size, the 
pain decreased, and healing was achieved after 9 
months from the start of the last treatment. The pa-
tient continued to apply the topical cream with Vita-
min E locally (Figure 1, D); 24 months after the ulcer 
healing, the skin surface is completely devoid of al-
terations (Figure 2).
DISCUSSION
The pathogenesis of leg ulcers in SCD includes dif-
ferent factors, such as vessel obstructions by dense 
sickled cells, trauma, insect bites, lactic acid dehy-
drogenase (LDH) values, in situ thrombosis, anemia, 
low socio-economic status, and abnormal autonomic 
control with excessive vasoconstriction; in addition, 
warm and humid climates also play a pivotal role 
(1,2,5). Increased nitric oxide (NO) catabolism and re-
duced NO production due to arginine deficiency lead 
to vasoconstriction, thereby reducing blood flow and 
exacerbating local ischemia (5).
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Figure 2. After 24 months since the ulcer healed, the 
skin surface is completely devoid of alterations.
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HU, a cytostatic agent, has demonstrated efficacy 
in improving health outcomes for children with SCD 
who have medical complications (6-8). However, this 
drug is known to produce several adverse cutaneous 
side effects, including leg ulceration. The leg ulcer 
that occurred in our young patient with SCD seemed 
to be worsened by the use of HU. 
Since the crucial point is to prevent the onset of 
a leg ulcer through hygiene, reducing venous stasis, 
and avoiding traumas, the standard treatment of this 
complication includes wound care with wet to dry 
dressings leading to healing in a few weeks (2). In 
persistent ulcers, other therapeutic strategies are re-
quired: blood transfusion, skin grafting, Unna boots, 
zinc sulphate, hyperbaric oxygen, arginine butyrate, 
and topical herbal applications (2). NPWT is a treat-
ment usually employed for infected ulcers, especially 
with involvement of the bone tissue (3,9). It is a new 
method utilized in wound care which speeds wound 
healing by creating a vacuum, improving tissue per-
fusion, and suctioning the exudates (3). The use of 
collagenase is normally based on performing lysis of 
fibrin and necrotic tissue, allowing the regeneration 
of a new extracellular matrix and favoring the migra-
tion of fibroblasts and keratinocytes.
There is also some evidence for the efficacy of 
PLT-gel in treating resistant chronic ulcers. PLT-gel re-
leases growth factors and cytokines able to stimulate 
the proliferation, migration, and differentiation of fi-
broblasts and endothelial cells (4,9,10). It also forms 
a biological scaffold that helps and guides the migra-
tion of the mesenchymal cells, derived from popula-
tions of resident stem cells or circulating precursors, 
from the base and the margins of the wound (10-12). 
Unfortunately, all the above-mentioned strategies 
were unsuccessful in our patient.
HU discontinuation, antibiotic therapy, and several 
transfusions showed to be effective when combined 
with enoxaparin, a LMWH, resulting in improvement 
in the leg ulcer. According to the literature, the use 
of LMWH appears to be associated with rapid and ef-
fective endothelial cell repair  and enhanced angio-
genesis as well as neo-vascularization (13-14). LMWH 
exerts its major anticoagulant effect by binding to an-
tithrombin via a pentasaccharide, consequently inac-
tivating factor Xa and factor IIa. Furthermore, LMWH 
has anti-inflammatory properties in addition to its 
anticoagulant properties, in part induced by suppres-
sion of tumor necrosis factor alpha, which is released 
during blood clotting, and in part because of bind-
ing to P-selectin to inhibit leukocyte migration. Vaso-
occlusion also leads to an altered NO (vasodilator) 
metabolism and contributes to vascular dysfunction, 
whereas LMWH increases NO production and en-
hances vasodilation effects (15-19. Heparin, with its 
antithrombotic and anticoagulant effects, may then 
interrupt the natural disease progression of an ulcer, 
increasing its chances of recovery. We did not observe 
any side effects due to LMWH (such as bleeding) and, 
even if the transfusion requirements remained un-
changed before and after the introduction of LMWH, 
there was a marked improvement in the ulcer. This 
supports the role of LMWH as a possible and useful 
treatment in ulcers that occur in patients with SCD. 
Finally, a good response was observed with the 
use of Vitamin E as co-adjuvant in the treatment of 
the leg ulcer. Vitamin E induces vasodilatation, reduc-
es the ischemic damage, and induces re-epitheliza-
tion by increasing the expression of cytosolic phos-
pholipase A2 and cyclooxygenase (20).
CONCLUSION  
LMWH should be used to facilitate the healing of 
chronic leg ulcers in patients with SCD. A systemic, 
supportive treatment that includes an adequate 
blood transfusion regimen, broad spectrum antibiot-
ics, and local therapy with Vitamin E, could contribute 
reducing healing time and pain (20).
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